Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.
PER Pulse™ Recap
from the 20th Annual International Congress on Hematologic Malignancies® focuses on multiple myeloma (MM), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
This activity is supported by educational grants from AbbVie; Ariad Pharmaceuticals, Inc; Baxalta US Inc; Bristol-Myers Squibb; Celgene; Genentech, Inc; Gilead; Incyte Corporation; Infinity Pharmaceuticals, Inc; Novartis Pharmaceuticals Corporation; Pharmacyclics LLC and Janssen Biotech, Inc; Seattle Genetics; Takeda Oncology; and TG Therapeutics, Inc.
Community Practice Connections™: 20th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma consists of a series of interactive clinical vignettes, short video interviews of leading experts in hematologic malignancies, and short summaries of clinical data related to these issues. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting.
Instructions For This Activity & Receiving Credit
This educational activity is directed toward community-based hematologists and medical oncologists, as well as fellows involved in the treatment and management of patients with hematologic malignancies. Nurse practitioners (NPs), nurses, physician assistants (PAs), pharmacists, researchers, and other healthcare professionals interested in the treatment of hematologic malignancies may also participate.
Andre Goy, MD, MS
Chairman and Director, Chief of Lymphoma
Director, Clinical and Translational Cancer Research
John Theurer Cancer Center at Hackensack University Medical Center
Professor of Medicine, Georgetown University
Elias Jabbour, MD
Associate Professor, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Sagar Lonial, MD, FACP
Professor, Emory School of Medicine
Chair, Department of Hematology & Medical Oncology
Chief Medical Officer
Winship Cancer Institute of Emory University
Susan O'Brien, MD
Associate Director for Clinical Science
Medical Director of the Sue and Ralph Stern Center
for Cancer Clinical Trials and Research
Chao Family Comprehensive Cancer Center
University of California, Irvine
The following individuals have no relevant financial relationships with commercial interests to disclose:
Elias Jabbour, MD, and the staff of Physicians' Education Resource®, LLC.
The following individuals have relevant financial relationships with commercial interests to disclose:
Andre Goy, MD, MS -- Grant/Research Support: JNJ, Celgene -- clinical trial support through institution; Consultant: Celgene; Speaker's Bureau: Takeda; JNJ/Pharmacyclics; Other: Member on Advisory Board: Celgene, Takeda, Pharmacyclics, JNJ; Sagar Lonial, MD, FACP -- Consultant: Novartis, Onyx, Millennium, BMS, Sanofi, Celgene, Janssen; Susan M. O'Brien, MD -- Grant/Research Support: Acerta Pharma, TG Therapeutics, Regeneron, Gilead Sciences, Pharmacylics, ProNAi Therapeutics; Consultant: Amgen, Celgene.
It is the policy of Physicians' Education Resource®, LLC, (PER®) to ensure fair balance, independence, objectivity, and scientific rigor in all of our CME/CE activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as a part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
This CME/CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
ONS: PER Forum™: Nursing Opportunities to Improve Outcomes With the Advent of PARP Inhibitors in the Care of Women’s Cancers
May 17, 2018
ONS: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for Nurses
May 17, 2018
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of Cancers
May 30, 2018
May 31, 2018
May 31, 2018